

VIRGINIA MASON CONTINUING MEDICAL EDUCATION

The 7th Virginia Mason Update in Inflammatory Bowel Disease

PRESENTED BY The Digestive Disease Institute at Virginia Mason

Friday, March 22, 2019

Virginia Mason • Seattle, Washington



Virginia Mason™

Faculty

COURSE DIRECTORS:

Michael Chiorean, MD, AGAF, FASGE

Program Director, Inflammatory Bowel Disease Center of Excellence
Digestive Disease Institute at Virginia Mason, Seattle, Wash.

Elisa Boden, MD

Inflammatory Bowel Disease Center of Excellence
Digestive Disease Institute at Virginia Mason
Research Assistant, Benaroya Research Institute, Seattle, Wash.

KEYNOTE SPEAKER:

Brian G. Feagan, MD

Professor of Medicine, Epidemiology and Biostatistics
Western University
Senior Scientific Officer, Robarts Clinical Trials Inc.
London, Ontario, Canada

FACULTY:

Russell K. Dorer, MD, PhD

Pathologist
Virginia Mason, Seattle, Wash.

Jason W. Harper, MD

Director, Inflammatory Bowel Disease Program, Harborview Medical Center
Clinical Assistant Professor, University of Washington Medicine
Seattle, Wash.

James Lord, MD, PhD

Inflammatory Bowel Disease Center of Excellence
Digestive Disease Institute at Virginia Mason, Seattle, Wash.

Vlad V. Simianu, MD, MPH

Colorectal Surgeon
Virginia Mason, Seattle, Wash.

Timothy Zisman, MD, MPH

Associate Professor of Medicine
Inflammatory Bowel Disease Program, Division of Gastroenterology
University of Washington Medical Center, Seattle, Wash.

The 7th Virginia Mason Update in Inflammatory Bowel Disease

PRESENTED BY The Digestive Disease Institute at Virginia Mason

The 7th Update in Inflammatory Bowel Disease course will review new and forthcoming medical and surgical therapeutic approaches in IBD and its associated manifestations, as well their impact on the current management of these conditions. The therapeutic landscape in IBD is changing very fast, resulting in rapid and dramatic changes to therapeutic algorithms and disease monitoring. The course will review the impact of positioning new therapeutics, optimization of medical therapy, disease management in pregnancy, alternative therapeutics and multi-disciplinary approaches to complex clinical scenarios including abscesses and fistulas. It will also cover novel therapies including the advent of biosimilar drugs and their impact in the management of IBD patients.

Teaching methods include lecture, panel discussion, audience response, case presentation and question-and-answer with faculty.

TARGET AUDIENCE: This course is appropriate for physicians in internal medicine, gastroenterology, general surgery, colorectal surgery, obstetrics, immunology, radiology and hospital medicine. This course is also appropriate for residents and advanced practice providers with an interest in inflammatory bowel disease.

OBJECTIVES:

At the conclusion of this activity, participants should be able to:

- Evaluate how personalized medicine will change the management of IBD
- Summarize the clinical data on tofacitinib in ulcerative colitis
- Summarize the evidence on current biologic therapies for ulcerative colitis
- Apply concepts of personalized medicine to clinical practice
- Discuss individualized approaches to the management of pregnant patients with IBD
- Assess the potential impact of new therapeutic classes in IBD
- Evaluate the risk/benefit balance of using cannabis products as therapeutic agents
- Compare different approaches to IBD complications through case presentations
- Review current IBD clinical trials at Virginia Mason
- Discuss strategies to minimize complications related to intra-abdominal abscesses
- Summarize elements of the pathological diagnosis of IBD
- Review the data on efficacy and safety of different therapeutic classes for perianal fistulas
- Discuss surgical approaches for perianal Crohn's disease



Accreditation with Commendation: The Virginia Mason Medical Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation: The Virginia Mason Medical Center designates this live activity for a maximum of **6.5 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of

Agenda

- 7:00 a.m. Registration opens, breakfast selection available
- 7:30 a.m. **GRAND ROUNDS PRESENTATION:**
The Changing Landscape of IBD Management | Brian Feagan, MD
- 8:30 a.m. Break
- 8:45 a.m. **Introduction, Overview of Course Objectives** | Michael Chiorean, MD
- 8:50 a.m. **Debate: Tofacitinib Should Be Used as First Line Agent in Ulcerative Colitis** | Tim Zisman, MD
- 9:15 a.m. **Debate: Tofacitinib Should Not Be Used as First Line Agent in Ulcerative Colitis** | James Lord, MD, PhD
- 9:45 a.m. **State of the Art Management of Ulcerative Colitis** | Michael Chiorean, MD
- 10:10 a.m. **Pregnancy and IBD** | Elisa Boden, MD
- 10:30 a.m. **Q & A with Faculty**
- 10:40 a.m. Break
- 11:00 a.m. **New Drugs in the Pipeline** | James Lord, MD, PhD
- 11:30 a.m. **Cannabis in IBD: Weeding out the Truth** | Jason Harper, MD
- 12:00 p.m. Lunch (provided)
- 1:00 p.m. **Case Presentations**
Panel: Elisa Boden, MD; Michael Chiorean, MD; James Harper, MD; James Lord, MD, PhD; Tim Zisman, MD
- 1:15 p.m. **Clinical Trials at Virginia Mason** | Michael Chiorean, MD
- 1:30 p.m. **Medical Management of Intra-abdominal Abscesses in Crohn's Disease**
Elisa Boden, MD
- 1:55 p.m. **Pathology to the Rescue: IBD Diagnosis, Monitoring and Mimics**
Russel Dorer, MD
- 2:20 p.m. **Q & A with Faculty**
- 2:25 p.m. **Medical Management of Fistulas: Antibiotics to Stem Cells**
Michael Chiorean, MD
- 2:55 p.m. **Perianal Disease: Surgical Approaches** | Val Simianu, MD
- 3:30 p.m. **Final Q&A, Closing Remarks**
- 3:45 p.m. Adjourn

CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Nursing Contact Hours: Virginia Mason is a provider of nursing continuing education contact hours. Provider is approved by the California Board of Registered Nursing, Provider #CEP15905 for 6.5 Contact Hours (6.5 clock hours), March 22, 2019.

Location: The course will be held in Volney Richmond Auditorium on Level One of the Virginia Mason Lindeman Pavilion, 1201 Terry Avenue, Seattle (between Seneca & University Streets.) *Please note the Terry Street entrance into Lindeman Pavilion is Level Two.* For information, contact the CME Department at 206-341-0142 or email cme@virginiamason.org.

To register, complete the form below and send via:



MAIL:

Virginia Mason CME Dept.
1100 Ninth Ave., D3-CME
Seattle, WA 98101



PHONE: 206-341-0142



FAX: 206-341-1480



E-MAIL: CME@VirginiaMason.org

WEB: VirginiaMasonCME.org

Cancellation and Refund Policy: Refunds will be made for a fee of \$25 if written notice of cancellation is received at least 14 calendar days prior to the activity.

Registration

The 7th Virginia Mason Update in Inflammatory Bowel Disease

Friday, March 22, 2019



Please print clearly

NAME _____ DEGREE/CREDENTIALS _____

SPECIALTY _____

ORGANIZATION _____

ADDRESS _____

CITY/STATE/ZIP _____

PHONE _____ E-MAIL _____

Please provide one question for the faculty: _____

I will attend at the Videoconferencing Site in: _____

For information, call 206-341-0142.

Please add me to your e-mail list for news of upcoming CME courses at Virginia Mason.

PAYMENT:

Tuition:

- MD/DO/Allied Health Professional: \$195.00
- Residents/Fellows: Contact the CME Department for pricing information
- Check enclosed. Make check payable to Virginia Mason CME
- Please charge my: VISA MasterCard American Express Discover

CARD NUMBER _____ EXPIRATION DATE _____

CARDHOLDER NAME _____ SIGNATURE _____